🔷 This comprehensive update incorporates the latest evidence published since the previous guideline, with changes that may have a meaningful impact on clinical practice.
🔗 Read more: bit.ly/ONCOnews04Fe...
#ONCOnews #OncoAlert #OncEd #ASCOGuidelines #LivingGuideline #NSCLC #NonSmallCellLungCancer
▪️ ASCO Living Guidelines are continuously reviewed and regularly updated by experts to reflect emerging evidence.
🔗 Read more: bit.ly/ONCOnews21J-01
#ONCOnews #OncoAlert #OncEd #ProstateCancer #ASCOGuidelines #mCRPC #GenitourinaryCancer
Here is a great @ascocancer.bsky.social JCO #ASCOGuidelines resource ascopubs.org/doi/10.1200/... #SymptomScience
@ascocancer.bsky.social Guideline update! Systemic Therapy in Patients with metastatic Castration-Resistant Prostate Cancer #ASCOGuidelines @brittanyeharvey.bsky.social @beverlymoy.bsky.social @latinamd.bsky.social www.asco.org/guidelines/G...
On the @ascocancer.bsky.social guidelines podcast, Dr. Nimish Mohile & Dr. Jaishri Blakeley review the evidence from the INDIGO trial that prompted this guideline update, and how to incorporate the use of vorasidenib into clinical practice #ASCOguidelines #oncsky podcasts.apple.com/us/podcast/t...
Visual Abstract for ASCO-SNO Guideline Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults Rapid Guideline Update Oligodendroglioma, IDH-mutant, 1p19q co-deleted, CNS WHO grade 2 Options Include: - RT + PCV - When toxicity is a concern, RT + temozolimide - For some people with favorable prognostic factors or concerns about toxicity, deferred RT + chemotherapy until radiographic or symptomatic progression - After 1+ surgeries, when RT + chemotherapy has been or can be deferred, vorasidenib may be offered Astrocytoma, IDH-mutant, 1p19q non-codeleted, CNS WHO grade 2 Options include: - RT + adjuvant chemotherapy (temozolimide or PCV) - For some people with favorable prognostic factors or concerns about short- and long-term toxicity, deferred RT + chemotherapy until radiographic or symptomatic progression - After 1+ surgeries, when RT + chemotherapy has been or can be deferred, vorasidenib may be offered Mohile et al J Clin Oncol 2025 asco.org/neurooncology-guidelines
Rapid recommendation update from @ascocancer.bsky.social & @neuroonc.bsky.social on therapy for diffuse astrocytic & oligodendroglial tumors in adults #ASCOguidelines #oncsky #medsky
ascopubs.org/doi/full/10....
I spoke with Clara Park @ Brigham & Women's & Mylin Torres from @winshipatemory.bsky.social about this latest SLNB guideline update. We discuss the recommendations, importance of shared decision-making and other ongoing & future de-escalation trials #ASCOguidelines podcasts.apple.com/us/podcast/s...
ASCO Guidelines Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer Guideline Update This guideline updates recommendations on the use of SLNB in patients with early-stage breast cancer treated with initial surgery, and includes the following topics: When SLNB can be omitted When ALND is indicated Radiation and systemic treatment decisions after SLNB omission Role of SLNB in special circumstances Park et al J Clin Oncol 2025 asco.org/breast-cancer-guidelines
Our latest guideline update on sentinel lymph node biopsy in patients with early-stage breast cancer treated with initial surgery @ascocancer.bsky.social #ASCOguidelines #MedSky #OncSky
Protocol for future ASCO guideline on patient-reported outcomes available for comment through Wednesday, April 9 @ascocancer.bsky.social #ASCOguidelines #OncSky #MedSky app.smartsheet.com/b/form/ecf22...
Dr. Irene Su from @ucsdhealthsci.bsky.social & Dr. Alison Loren from @pennmedicine.bsky.social joined me on the #ASCOguidelines podcast to discuss this fertility preservation guideline update, including the new recommendations, current challenges & ongoing research podcasts.apple.com/us/podcast/f...
Protocol for the @ascocancer.bsky.social guideline update on management of immune-related adverse effects available for open comment through March 19 #ASCOguidelines #irAEs #MedSky #OncSky #SuppOnc app.smartsheet.com/b/form/e3689...
Dr. Lyudmila Bazhenova from @ucsdhealthsci.bsky.social provides an overview of the stage IV NSCLC without driver alterations guideline update on the #ASCOguidelines podcast, including evidence reviewed and what this update means for clinicians & patients podcasts.apple.com/us/podcast/t...
Visual abstract describing updated recommendations in the 2024.3 version of the therapy for stage IV NSCLC without driver alterations guideline
Updates just released for two companion living @ascocancer.bsky.social guidelines on stage IV NSCLC
Updated recommendations for stage IV NSCLC without driver alterations include a new second-line option for patients with good PS & HER2 overexpression #ASCOguidelines
ascopubs.org/doi/10.1200/...
Dr. Chris Holsinger from @stanfordmedicine.bsky.social discusses these new recommendations on TORS for patients with OPC, the importance of multidisciplinary collaboration & shared decision-making between patients & clinicians on the #ASCOguidelines podcast podcasts.apple.com/us/podcast/t...
ASCO Guidelines Transoral Robotic Surgery in the Multidisciplinary Care of Patients with Oropharyngeal Squamous Cell Carcinoma Guideline update including recommendations on: Evaluation & Workup of Patients with OPC for TORS Goal of TORS Patient Selection Adjuvant Therapy Role of TORS in HPV-negative OPC Use of TORS in Salvage or Recurrent Setting Holsinger et al J Clin Oncol 2025 asco.org/head-neck-cancer-guidelines
New evidence-based @ascocancer.bsky.social guideline out on TORS in the multidisciplinary care of patients with oropharyngeal squamous cell carcinoma #ASCOguidelines
ascopubs.org/doi/full/10....
Dr. Stephanie Gaillard from Johns Hopkins University and Dr. Bill Tew from @mskcancercenter.bsky.social discuss the NACT for ovarian cancer recommendation updates, the evidence underpinning these changes, and the importance of this guideline on the #ASCOguidelines podcast tinyurl.com/52xb6edm
ASCO Guidelines Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer Guideline update including recommendations on: Initial Assessment Primary Cytoreductive Surgery Neoadjuvant Chemotherapy Confirmation of Diagnosis Preferred Chemotherapy Regimens Timing of Interval Cytoreductive Surgery Role of Hyperthermic Intraperitoneal Chemotherapy Recommended Number of Chemotherapy Cycles Maintenance Therapy Options for Patients with Progressive Disease on Neoadjuvant Chemotherapy Gaillard et al J Clin Oncol 2025 asco.org/gynecologic-cancer-guidelines
New update to the neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer from @ascocancer.bsky.social covering many evidence-based recommendations on the use of NACT across ten clinical questions #ASCOguidelines #medsky #oncsky ascopubs.org/doi/full/10....
Dr. Evan Yu from @fredhutch.bsky.social discusses which patients with metastatic prostate cancer should receive germline & somatic testing with NGS technologies, what samples are preferred & therapeutic & prognostic impacts of testing on the #ASCOguidelines podcast podcasts.apple.com/us/podcast/g...
ASCO Guidelines Germline & Somatic Genomic Testing for Metastatic Prostate Cancer Includes algorithm on flow of genomic/somatic testing and genetic testing for all patients with metastatic prostate cancer. Yu et al J Clin Oncol 2025 asco.org/genitourinary-cancer-guidelines
Latest guideline from @ascocancer.bsky.social on germline & somatic genomic testing for metastatic prostate cancer published today #ASCOguidelines #medsky #oncsky ascopubs.org/doi/full/10....
Dr. Hedy Kindler discussed these latest changes to evidence-based recommendations on the treatment of pleural mesothelioma with me on a new episode of the #ASCOguidelines podcast #medsky #oncsky podcasts.apple.com/us/podcast/t...
ASCO Guidelines: Treatment of Pleural Mesothelioma Guideline update including recommendations on: Diagnosis and Staging, Surgery, Immunotherapy, Chemotherapy, Radiation Therapy, Pathology, Germline Testing Kindler et al J Clin Oncol 2025 asco.org/thoracic-cancer-guidelines
New Treatment of Pleural Mesothelioma Guideline Update just released from @ascocancer.bsky.social! Includes recommendations on diagnosis & staging, surgery, immunotherapy, chemotherapy, radiation therapy, pathology & germline testing #ASCOguidelines #medsky #oncsky ascopubs.org/doi/full/10....
@jama.com #scanxiety RCT of CBD v placebo in women with #breastcancer (n=50) led by @ascocancer.bsky.social Cannabis #ASCOGuidelines Co-Chair, Dr. Ilana Braun. No difference primary end point (VAMS afraid subscale). More work to be done #PallOnc #SymptomScience jamanetwork.com/journals/jam...
Dr. @vanmorrismd.bsky.social discussed the new evidence-based guideline on systemic therapy for localized anal squamous cell carcinoma with me on the #ASCOguidelines podcast - highlighting key recs, considerations for special populations & future research areas podcasts.apple.com/us/podcast/s...
New guideline just out from ASCO on systemic therapy for stage I-III anal squamous cell carcinoma #ASCOguidelines #MedSky #OncSky ascopubs.org/doi/full/10....
ASCO Anal Cancer Guideline published today. Thanks to our expert panel for all your hard work! #ASCOGuidelines @ascocancer.bsky.social @vanmorrismd.bsky.social @beverlymoy.bsky.social @brittanyeharvey.bsky.social @latinamd.bsky.social @advocatecollab.bsky.social #OncSky ascopubs.org/doi/full/10....
@ascocancer.bsky.social #ASCOGuidelines out today "Systemic Therapy for Stage I-III Anal Carcinoma" with guidance about radiosensitization, dose/scheduling options, and much more. @vanmorrismd.bsky.social @cathyengmd.bsky.social Read at society.asco.org/practice-pat...
Welcome! @juliaclose.bsky.social our #ASCO Executive VP & Chief Education Officer @tmprowell.bsky.social @brittanyeharvey.bsky.social @beverlymoy.bsky.social @jrgralow.bsky.social @pallonccop.bsky.social @jillfeldman4.bsky.social @ishwaria.bsky.social @funchainmd.bsky.social #ASCOGuidelines #ASCOESP
Visual abstract for Systemic Therapy for SCLC Rapid Guideline Update: 2.4. Patients with LS-SCLC who have completed concurrent chemoradiotherapy and do not have disease progression should be offered consolidation immunotherapy (durvalumab) for up to 2 years if there are no contraindications to immunotherapy. (Evidence quality: Moderate; Strength of recommendation: Strong) 5.3.1. Patients with LS-SCLC and ECOG PS 3-4 due to SCLC who have been treated with concurrent or sequential chemotherapy and radiotherapy may be offered consolidation immunotherapy (durvalumab) for up to 2 years if there are no contraindications to immunotherapy and there is improvement in PS. (Evidence quality: Low; Strength of recommendation: Conditional) 4.1. In patients with relapsed SCLC with a chemotherapy-free interval of less than 90 days, single-agent systemic therapy may be offered. Preferred agents are topotecan, lurbinectedin or tarlatamab. (Evidence quality: Moderate; Strength of recommendation: Strong) 4.2. In patients with relapsed SCLC with a chemotherapy-free interval of at least 90 days, re-challenge with a platinum-based regimen or single-agent chemotherapy (preferred agents are topotecan, lurbinectedin or tarlatamab) may be offered. (Evidence quality: Moderate; Strength of recommendation: Strong) Kalemkerian et al J Clin Oncol 2024 asco.org/thoracic-cancer-guidelines
New rapid recommendation update on systemic therapy for small-cell lung cancer from ASCO just published: ascopubs.org/doi/full/10.... #ASCOguidelines #MedSky #OncSky #LCSM
The "Living" #ASCOGuidelines embraces change and supports #OncSky clinicians and people LIVING with mutation-driven lung cancer in making informed treatment choices. Congrats to the expert panel! ascopubs.org/doi/full/10.... @jillfeldman4.bsky.social #LCSM
I spoke with co-chair Dr. Lyudmila Bazhenova from UCSD about this latest stage IV NSCLC living guideline update on the #ASCOguidelines podcast, discussing evidence from MARIPOSA, MARIPOSA-2, CheckMate 722 & KEYNOTE-789 that informed these updated recommendations podcasts.apple.com/us/podcast/a...
